INVESTOR ALERT: Investigation on Behalf of Alcobra Ltd. Shareholders Announced by Glancy Binkow & Goldberg LLP

Glancy Binkow & Goldberg LLP announces that it is investigating potential claims on behalf of shareholders of Alcobra, Ltd. (“Alcobra” or the “Company”) (NASDAQ:ADHD) concerning possible violations of federal securities laws by misleading investors regarding the results of the Phase III study of Alcobra’s experimental drug MDX for treatment of Adult ADHD.

Please contact Casey Sadler or Lesley Portnoy at (310) 201-9150, or at shareholders@glancylaw.com to discuss this matter. If you inquire by email, please include your mailing address, telephone number and number of shares purchased.

On October 6, 2014, the Company announced topline results from its Phase III study of MDX in Adult ADHD, and declared that MDX demonstrated a statistically significant improvement in ADHD symptoms. The Company further stated that only after removing 4 patients with extreme placebo responses did MDX demonstrate statistical significance in improving patient symptoms. An analyst report published on October 6, 2014 by Adam Feurstein entitled, “Alcobra ADHD Drug Fails Key Study except When Patients Removed From Analysis,” echoed the market’s sentiment that MDX in fact did not meet statistical significance when accounting for all trial participants. In response the Company’s shares fell over 60% or $7.99 per share, on October 6, 2014, to close at $6.12 per share on heavy volume.

Then on October 22, 2014, the Company announced that the MDX Phase III study in fact did not demonstrate a statistically significant improvement in patient symptoms, stating in relevant part, “While a complete ITT analysis by ADHD subtypes is still ongoing and was not presented at AACAP, the magnitude of symptom improvement appears to be similar in all subtypes, and the Predominantly-Inattentive ADHD (PI-ADHD) subtype alone did not produce a statistically significant outcome." On this news Alcobra shares fell 36% or $2.05 per share, over the course of two trading sessions to close on October 24, 2014 at $3.63 per share.

If you purchased Alcobra shares prior to October 22, 2014, if you have information, or would like to learn more, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Casey Sadler, Esquire, or Lesley F. Portnoy, Esquire of Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067, Toll Free at (888) 773-9224, by e-mail to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.